Core Viewpoint - The announcement highlights a strategic partnership between YuanDa Pharmaceutical and YouEr Pharmaceutical for the commercialization of Neffy, the world's first epinephrine nasal spray for emergency treatment of type I allergic reactions in mainland China and Hong Kong [1] Group 1: Partnership Details - YuanDa Pharmaceutical has secured exclusive commercialization rights for Neffy in mainland China and non-exclusive rights in Hong Kong [1] - The partnership includes two formulations of Neffy: 2mg for adults and children over 30kg, and 1mg for children weighing between 15-30kg [1] Group 2: Regulatory Progress - Neffy has submitted its application for market approval to the National Medical Products Administration (NMPA) in December 2024, and the application has been accepted [1]
远大医药：引进全球首款治疗严重过敏反应的肾上腺素鼻喷雾剂